Description
For research purposes only. Not for human consumption. For use by licensed researchers only.
Retatrutide is a next-generation triple receptor agonist targeting GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. It represents an advance in metabolic peptide research for more comprehensive investigation of obesity, metabolic disease, and energy regulation.
Mechanism of Action
By activating all three incretin and glucagon receptors, Retatrutide creates a multifaceted metabolic response: GLP-1 receptor agonism improves insulin secretion and reduces appetite; GIP receptor activation modulates fat metabolism and enhances incretin effects; glucagon receptor activation increases energy expenditure and supports hepatic glucose regulation. Research suggests this triple mechanism produces superior metabolic outcomes compared to dual agonism.
Research Applications
- Obesity and severe metabolic disease research
- Triple incretin receptor signaling studies
- Energy expenditure and thermogenesis models
- Hepatic lipid metabolism and steatosis research
- Next-generation metabolic compound mechanism studies
Research Grade Peptide
| Compound | Retatrutide |
| Strength | 10 MG |
| Vial Size | 3 ML |
| Vial Color | Clear |
| Form | Lyophilized Powder |
| Purity | >98% (HPLC verified) |
| Price | $350 |
This compound is provided strictly for in vitro and laboratory research. Not intended for human or animal use.
